{
  "id": 20311196,
  "title": "FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder",
  "url": "https://urgent.news/2026/11/16/fda-clears-tevas-newly-acquired-at-home-agitation-treatment-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-16T18:11:19.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/news/fda/26/11/63310036/fda-clears-tevas-newly-acquired-at-home-agitation-treatment-in-schizophrenia-and-bipolar-disorder"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd.'s acquisition of IGALMI, a sublingual film used for at-home treatment of acute agitation in adults with schizophrenia, schizoaffective disorder, or bipolar disorder I or II. This marks the first FDA-approved treatment for patients to administer at home. The FDA's decision follows a Phase 3 trial that demonstrated consistent tolerability in 1,160 agitation episodes across 102 patients, with no participants discontinuing treatment due to side effects. Adverse events included somnolence, dry mouth, dizziness, and oral paresthesia or hypoesthesia. Teva paid $57.5 million upfront for the rights to IGALMI, with potential additional payments totaling $67.5 million. Following the acquisition, Teva's stock price was down 2.40% at $43.43.",
  "summary": "Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use. This regulatory decision makes IGALMI the first FDA-approved treatment that adults can use at home for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. IGALMI…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}